NasdaqGM:UBIO

Stock Analysis Report

ProShares Trust - ProShares UltraPro Nasdaq Biotechnology

Executive Summary

ProShares Trust - ProShares UltraPro Nasdaq Biotechnology is an exchange traded fund launched and managed by ProShare Advisors LLC.


Snowflake Analysis

Share Price & News

How has ProShares Trust - ProShares UltraPro Nasdaq Biotechnology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: UBIO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.5%

UBIO

0.4%

US Capital Markets

0.06%

US Market


1 Year Return

17.0%

UBIO

17.9%

US Capital Markets

19.3%

US Market

Return vs Industry: UBIO matched the US Capital Markets industry which returned 17.9% over the past year.

Return vs Market: UBIO underperformed the US Market which returned 19.3% over the past year.


Shareholder returns

UBIOIndustryMarket
7 Day1.5%0.4%0.06%
30 Day4.9%0.7%1.7%
90 Day17.7%6.9%9.0%
1 Year17.0%17.0%20.2%17.9%21.8%19.3%
3 Year26.9%26.9%40.2%32.4%49.5%39.9%
5 Yearn/a84.5%67.4%73.1%54.1%

Price Volatility Vs. Market

How volatile is ProShares Trust - ProShares UltraPro Nasdaq Biotechnology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ProShares Trust - ProShares UltraPro Nasdaq Biotechnology undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether ProShares Trust - ProShares UltraPro Nasdaq Biotechnology is trading at an attractive price based on the cash flow it is expected to produce in the future. But as ProShares Trust - ProShares UltraPro Nasdaq Biotechnology has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.

Future Growth

How is ProShares Trust - ProShares UltraPro Nasdaq Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

8.5%

Forecasted Diversified Financials industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ProShares Trust - ProShares UltraPro Nasdaq Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has ProShares Trust - ProShares UltraPro Nasdaq Biotechnology performed over the past 5 years?

16.6%

Historical Diversified Financials annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, ProShares Trust - ProShares UltraPro Nasdaq Biotechnology has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.

Financial Health

How is ProShares Trust - ProShares UltraPro Nasdaq Biotechnology's financial position? (This company is analysed differently as a bank or financial institution)


In this section we usually analyse ProShares Trust - ProShares UltraPro Nasdaq Biotechnology's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. ProShares Trust - ProShares UltraPro Nasdaq Biotechnology has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.

Dividend

What is ProShares Trust - ProShares UltraPro Nasdaq Biotechnology's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate UBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate UBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if UBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if UBIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of UBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

ProShares Trust - ProShares UltraPro Nasdaq Biotechnology has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

ProShares Trust - ProShares UltraPro Nasdaq Biotechnology's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ProShares Trust - ProShares UltraPro Nasdaq Biotechnology
  • Ticker: UBIO
  • Exchange: NasdaqGM
  • Founded: 2015
  • Industry: Asset Management and Custody Banks
  • Sector: Diversified Financials
  • Market Cap: US$0
  • Shares outstanding: 0
  • Website: https://www.proshares.com/funds/ubio.html

Location

  • ProShares Trust - ProShares UltraPro Nasdaq Biotechnology
  • 7501 Wisconsin Avenue
  • Suite 1000E
  • Bethesda
  • Maryland
  • 20814-6527
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
UBIONasdaqGM (Nasdaq Global Market)YesULTPRO NASBIO NWUSUSDJun 2015
PS56MUN (Boerse Muenchen)YesULTPRO NASBIO NWDEEURJun 2015

Biography

ProShares Trust - ProShares UltraPro Nasdaq Biotechnology is an exchange traded fund launched and managed by ProShare Advisors LLC. It invests in public equity markets of the United States. The fund invests directly and through derivatives in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences, sectors. It uses derivatives such as swaps to create its portfolio. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track 3x the daily performance of the Nasdaq Biotechnology Index, by using synthetic replication technique. ProShares Trust - ProShares UltraPro Nasdaq Biotechnology was formed on June 22, 2015 and is domiciled in the United States. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/21 02:22
End of Day Share Price2020/02/20 00:00
EarningsN/A
Annual EarningsN/A


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.